About us

Energenesis Biomedical Announces IND Submission to the U.S. FDA for Phase II Clinical Trial of ENERGI-F703EB Cream

Energenesis Biomedical is invited to attend Taishin’s “2025 Investor Conference"

Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease

Energenesis Biomedical and Medvisis Switzerland AG Sign MOU for F703DFU Commercialization in Switzerland

Energenesis Biomedical and Phison Sign MOU to Advance AI-Driven Drug Development

Energenesis Biomedical Co., Ltd. has signed a Memorandum of Understanding (MOU) with DEBRA Research gGmbH to collaborate on the development of F703EB.

Energenesis Biomedical has received CRO notification that its Phase I IND application for "ENERGI-F705PD," an oral Parkinson's treatment, has been conditionally approved by the Ministry of Health and Welfare to begin clinical trials.

Energenesis Biomedical Signs MOU with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, Japan, for the Commercialization Rights of F703DFU in Taiwan and Southeast Asia (ASEAN)

EB Announces Exclusive Licensing Agreement with PBI Portugal Unipessoal Lda., a wholly owned subsidiary of the German group Pharma Bavaria International

EB Receives Notification from CRO Regarding IND Submission to TFDA for Phase I Clinical Trial of ENERGI-F705PD, an Oral Treatment for Parkinson's Disease.